Released Aug 13, 2024, after the close
10-Q filed Aug 13, 2024, 44 days after period end · 0000950170-24-096336
Q2 2024 · 10-Q
Revenue$25.71M$25.71M +146.9% vs Q2 2023+97.6% vs Q1 2024
Net Income-$48.02M-$48.02M N/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.59-$0.59 N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$48,685,000N/M
Operating Cash Flowderived$9,455,000N/M
Margins · derived
Operating margin-189.4%+254.1 pt vs Q2 2023
Net margin-186.8%+183.2 pt vs Q2 2023
What the release said
The release
Same quarter
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $25.71M | $10.41M | $28.10M | $28.05M |
| Net Income | -$48.02M | -$38.52M | -$26.01M | -$6.15M |
| EPS Diluted | -$0.59 | -$0.64 | -$0.55 | -$0.13 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR